Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, R...

FDA Drug Recall #D-0738-2026 - Class III, July 16, 2026

Recall Summary

Recall Number D-0738-2026
Classification Class III, Low risk
Date Initiated July 16, 2026
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Ascend Laboratories, LLC
Location Bedminster, NJ
Product Type Drugs
Quantity 924 cartons x 12 x 6 x 10 (in blister pack)

Product Description

Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-68.

Reason for Recall

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Distribution Pattern

USA Nationwide

Lot / Code Information

Lot: 25141585, Exp. April 30, 2027.

Other Recalls from Ascend Laboratories, LLC

Recall # Classification Product Date
D-0739-2026 Class III Dabigatran Etexilate Capsules, 75 mg, 30-count ... Jul 16, 2026
D-0737-2026 Class III Dabigatran Etexilate Capsules, 150 mg, 60-count... Jul 16, 2026
D-0712-2026 Class II Amlodipine and Olmesartan Medoxomil Tablets, 10... Jul 8, 2026
D-0735-2026 Class III Dabigatran etexilate Capsules, 110 mg, 60-count... Jun 30, 2026
D-0736-2026 Class III Dabigatran etexilate Capsules, 150 mg, 20-count... Jun 30, 2026

Frequently Asked Questions

Nitrosamines are probable human carcinogens, they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.